How to Value a Veterinary Oncology Practice in 2026

Veterinary oncology is one of the most specialized — and most valuable — niches in veterinary medicine. The convergence of rising pet healthcare spending, advances in animal cancer treatment, and an extremely limited supply of board-certified veterinary oncologists has created a market where well-run practices command multiples that would surprise most veterinary professionals. I've worked on specialty veterinary transactions across the country, and oncology practices consistently trade at the top of the range.

The Multiples: 6-12x EBITDA

Veterinary oncology practices trade at 6-12x EBITDA, significantly above general practice veterinary multiples of 5-8x. The premium reflects three realities: extreme physician scarcity, high case revenue, and the essential role oncology plays in a veterinary specialty platform.

Where you fall in the 6-12x range depends primarily on your treatment capabilities and referral infrastructure. A practice limited to medical oncology (chemotherapy, immunotherapy) will trade at the lower end. A practice with both medical and radiation oncology — meaning you own a linear accelerator or have dedicated radiation therapy capabilities — commands the premium multiples. The reason is simple: radiation oncology creates a massive competitive moat. There are fewer than 100 veterinary radiation therapy facilities in the United States.

Board-Certified Oncologists: The Scarcest Asset in Veterinary Medicine

There are approximately 400 board-certified veterinary oncologists (ACVIM-Oncology) in the United States. The residency pipeline produces roughly 20-25 new diplomates per year. Meanwhile, demand for veterinary oncology services grows 8-12% annually as pet owners increasingly pursue advanced cancer treatment.

This supply-demand imbalance is the fundamental driver of veterinary oncology valuations. Every board-certified oncologist represents a revenue-generating asset that platform acquirers — Mars Veterinary Health, NVA, Thrive Pet Healthcare — cannot easily replace. When they acquire your practice, they're buying access to a specialist they couldn't recruit through conventional hiring.

The scarcity dynamic cuts both ways in a transaction. It justifies premium multiples, but it also creates key-person risk that buyers manage aggressively. Expect any acquisition offer to include a 3-5 year employment agreement with significant non-compete provisions, and potentially 20-30% of total consideration tied to retention and performance earn-outs.

Case Revenue and Fee Structure

Veterinary oncology case fees are among the highest in all of veterinary medicine. A typical cancer case generates $5,000-$15,000 in total revenue across diagnostics (staging CT, biopsy, bloodwork), treatment (chemotherapy protocols, radiation therapy), and follow-up monitoring. Complex cases involving multimodal therapy — surgery plus chemotherapy plus radiation — can exceed $20,000.

Buyers analyze your case revenue in granular detail:

Average revenue per case: This tells buyers about your treatment intensity and client willingness to pursue comprehensive protocols. Higher average case revenue generally signals a more committed client base.
New case volume per month: The number of new oncology consultations is your top-of-funnel metric. Growth in new cases means your referral network is strong and expanding.
Treatment mix: What percentage of cases proceed to treatment versus consultation only? A practice where 70%+ of consultations convert to treatment plans demonstrates strong client communication and realistic case selection.
Revenue per oncologist: A board-certified oncologist generating $1.5M-$2.5M in annual revenue is operating at a productive, sustainable level. Below $1M signals underutilization; above $3M suggests the physician may be overextended.

Linear Accelerator and Radiation Capability

If you own a linear accelerator, you hold one of the most defensible competitive positions in veterinary medicine. A veterinary linear accelerator costs $1.5M-$4M to purchase and install, requires a purpose-built vault with radiation shielding ($500K-$1M in construction), and needs a radiation safety program with state licensure. The barriers to entry are enormous.

Practices with radiation therapy capability serve as regional referral hubs — referring veterinarians within a 100-200 mile radius send cancer cases because there is simply nowhere else to go. This referral catchment area is, in effect, a geographic monopoly that generates consistent case volume regardless of competitive dynamics in general practice veterinary medicine.

Buyers pay premium multiples for radiation-capable practices because replicating this capability is a multi-year, multi-million dollar endeavor. The linear accelerator itself has a useful life of 10-15 years, and buyers will assess where you are in that lifecycle. A practice with a 3-year-old linac is worth meaningfully more than one with a 12-year-old unit approaching end of life.

Referral Volume and Network Strength

Veterinary oncology is almost entirely a referral-based specialty. General practice veterinarians diagnose or suspect cancer and refer to you. The strength, depth, and geographic reach of your referral network is a critical valuation driver that buyers examine closely.

What distinguishes a strong referral network from a fragile one:

Referring practice diversity. A practice receiving referrals from 100+ general practices has a diversified referral base that will survive the loss of any single referring veterinarian. A practice where 5 referring DVMs account for 60% of new cases has concentration risk that buyers will discount.

Referral growth trend. Buyers want to see new referring practices added each year. This signals that your reputation is growing and that you're actively cultivating relationships with the general practice community.

Communication quality. This is subtle but real: referring veterinarians send cases to oncologists who communicate well. Timely consultation reports, clear treatment plans shared with the primary vet, and collaborative case management build referral loyalty. Practices with a reputation for excellent referring-vet communication retain their referral networks even through ownership transitions.

What Drives Premium Veterinary Oncology Valuations

Multiple oncologists: A practice with 2-3 board-certified oncologists dramatically reduces key-person risk and signals institutional depth. This alone can add 2-3x EBITDA to your multiple.
Radiation therapy capability: Ownership of a functioning linear accelerator with remaining useful life is the single biggest premium driver.
Integrated specialty setting: Oncology practices co-located with surgery, internal medicine, and emergency services create a referral ecosystem that's greater than the sum of its parts.
Clinical trial participation: Practices involved in veterinary oncology clinical trials signal scientific credibility and attract cases from a wider geographic area.
Growing case volume: Consistent year-over-year growth in new oncology consultations at or above the 8-12% industry growth rate.

What Kills Veterinary Oncology Value

Solo oncologist with no succession. If you're the only board-certified oncologist and you haven't recruited a second, every buyer sees a practice that could go to zero if you leave. The math is unforgiving: it takes 7-8 years to train a veterinary oncologist from DVM to board certification. A buyer can't replace you quickly.

Aging or obsolete equipment. A linear accelerator nearing end of life, outdated CT scanner, or chemotherapy preparation area that doesn't meet current safety standards represent capital expenditures of $2M-$5M that buyers will deduct from their offer.

Geographic isolation without critical mass. Being the only oncology practice in a rural area sounds like a monopoly, but if the referral base within driving distance can't support 300+ new cases per year, the practice may be permanently capacity- constrained. Buyers need to see a path to growth.

Client demographic risk. Oncology depends on pet owners willing and able to spend $5K-$15K on cancer treatment. If your practice is in an area where the median household income doesn't support that level of spending, case conversion rates will be low and average case revenue will lag benchmarks.

The Bottom Line

Veterinary oncology practice valuation is driven by physician scarcity and treatment capability in a way that creates genuine premium multiples. The 6-12x EBITDA range reflects massive differences in practice infrastructure — from medical-oncology-only clinics to full radiation therapy centers with multiple specialists. If you're a veterinary oncologist contemplating an exit, the highest-impact moves are recruiting a second oncologist, maintaining your equipment, and building referral diversity so that no single source dominates your case pipeline. The consolidators are paying real premiums for well-run oncology practices — but only for those that can demonstrate sustainability beyond the founding physician.